Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States.
| Filed | Form | Activist | % of class | Conviction | |
|---|---|---|---|---|---|
| 2026-06-11 | SCHEDULE 13D | D. E. SHAW & CO, L.P. | 9.5% | Med | filing |
| 2026-02-24 | SCHEDULE 13D/A | Growth Equity Opportunities 18 VGE, LLC | 1.7% | Low | filing |
“I asked OpenAI Astra Ultra + Anthropic Fable 5.1 Max to make me a 5x-10x return type portfolio in 1 year. Burnt a lot of credits, and the results are in: OpenAI: - $KYTX (autoimmune CAR-T results) - $PRQR (human RNA-editing datasets) - $VSTM (KRAS cancer-drug) - $CNTB (asthma and COPD) - $RANI (oral biologics) - $IVA (MASH) - $SILC (networking + inference hardware) - $AMPX (batteries) - $EOSE …” post →
| Date | Tweet |
|---|---|
| 2026-09-06T14:23:02 | I asked OpenAI Astra Ultra + Anthropic Fable 5.1 Max to make me a 5x-10x return type portfolio in 1 year. Burnt a lot of credits, and the results are in: OpenAI: - $KYTX (autoimmune CAR-T results) - $PRQR (human RNA-editing datasets) - $VSTM (KRAS cancer-drug) - $CNTB (asthma and COPD) - $RANI (… → · 4993 likes · 1,338,791 views |
from2028 — cross-site stock view. Rebuilt at publish time.